Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine

Cell Mol Neurobiol. 2022 Jan;42(1):225-242. doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10.

Abstract

Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic properties. This multifaceted drug has a number of pharmacological and neurochemical effects in addition to inhibition of MAO, and findings on these effects have contributed to a body of evidence indicating that PLZ also has neuroprotective/neurorescue properties. These attributes are reviewed in this paper and include catabolism to the active metabolite β-phenylethylidenehydrazine (PEH) and effects of PLZ and PEH on the GABA-glutamate balance in brain, sequestration of reactive aldehydes, and inhibition of primary amine oxidase. Also discussed are the encouraging findings of the effects of PLZ in animal models of stroke, spinal cord injury, traumatic brain injury, and multiple sclerosis, as well other actions such as reduction of nitrative stress, reduction of the effects of a toxin on dopaminergic neurons, potential anticonvulsant actions, and effects on brain-derived neurotrophic factor, neural cell adhesion molecules, an anti-apoptotic factor, and brain levels of ornithine and N-acetylamino acids.

Keywords: Monoamine oxidase; Neuroprotection; Phenelzine; Reactive aldehydes; β-Phenylethylidenehydrazine; γ-Aminobutyric acid.

Publication types

  • Review

MeSH terms

  • Animals
  • Antidepressive Agents* / pharmacology
  • Monoamine Oxidase / metabolism
  • Monoamine Oxidase Inhibitors* / pharmacology
  • Neuroprotective Agents* / pharmacology
  • Phenelzine* / pharmacology
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antidepressive Agents
  • Monoamine Oxidase Inhibitors
  • Neuroprotective Agents
  • Monoamine Oxidase
  • Phenelzine